Magzter GOLD ile Sınırsız Olun

Magzter GOLD ile Sınırsız Olun

Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin

$149.99
 
$74.99/Yıl

Denemek ALTIN - Özgür

"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"

Bio Spectrum

|

BioSpectrum Indian Feb 2025

"In a recent development, Nagpur-based biotech company GeNext Genomics (GNG) has joined -hands with Merck Life Science to support the Indian biotech system, particularly in the area of biomanufacturing, which is garnering more attention after the approval of the BioE3 policy.Supriya Kashikar, Founder & Chief Executive Officer, GeNext Genomics shares her views with BioSpectrum on the growth of biomanufacturing sector in India, and how the company plans to play a relevant role in this aspect.

- Dr Manbeena Chawla

"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"

What are the key objectives of your recent collaboration with Merck? How will this partnership foster innovation and strengthen India’s position in the global biotech market?

The partnership combines Merck's biomanufacturing systems with GNG's Clone Development and HIND Antibody Library to drive biopharmaceutical innovation and position India as a hub for advanced R&D. The GNG-Merck collaboration creates a unique competitive edge for both companies by integrating local expertise with global biomanufacturing capabilities. Furthermore, Merck's expertise in both Upstream Processing (USP) and Downstream Processing (DSP) will support us in areas of biologics production, optimising cell culture yields, and refining end products to meet international standards.

This partnership is set to innovate and strengthen India’s biotech landscape:

● Platform Processes for Novel mAbs and Other Molecules: With Merck’s advanced bioprocessing systems installed at GNG, we’re positioned to efficiently develop and produce novel monoclonal antibodies (mAbs) and other therapeutic molecules. These processes ensure consistent, high-quality products that meet the highest global standards.

● Supporting Clone Development Services from India: With the integration of Merck’s systems into GNG’s Clone Development platform, we’re set to become a go-to provider for scalable clone development services. This will cater to a wide range of biotech firms, both in India and abroad.

● Infrastructure for Startups: Our collaboration creates a solid infrastructure for biotech startups, providing end-to-end support—from process development to clinical-phase production. This ensures that biotech startups in India can focus on innovation while we handle the complexities of scaling up.

Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum

Bio Spectrum

India's Pharma Reforms Target Global Credibility

The Indian government has introduced several measures to simplify drug approvals and support innovation.

time to read

9 mins

October 2025

Bio Spectrum

Bio Spectrum

How Waste Management Strategies Can Transform Indian Pharma Manufacturing

Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.

time to read

7 mins

October 2025

Bio Spectrum

Bio Spectrum

IASST synthesises new compound to combat aggressive breast cancer

A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.

time to read

1 min

October 2025

Bio Spectrum

DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem

In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

WHO unveils updated guideline on HIV service delivery

WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.

time to read

1 min

October 2025

Bio Spectrum

Scientists in Kolkata explore therapeutic potential of accessory proteins

A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.

time to read

1 min

October 2025

Bio Spectrum

Bio Spectrum

US FDA advances rare disease drug development

The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.

time to read

1 min

October 2025

Bio Spectrum

WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.

time to read

1 min

October 2025

Bio Spectrum

Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification

Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.

time to read

1 min

October 2025

Bio Spectrum

Aodh Lifesciences gets support from TDB to redefine pneumonia treatment

The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).

time to read

1 min

October 2025

Listen

Translate

Share

-
+

Change font size